Skip to main content
. 2023 Jul 10;120(29):e2214320120. doi: 10.1073/pnas.2214320120

Fig. 7.

Fig. 7.

Vaccines using iLNPs and PMs. (A and B) The in vivo CTL assay was performed at indicated schedules. iLNPs loading OVA mRNA with 0 or 1 tooth were injected into mice via i.m. route. n = 4. (B) PMs loading OVA mRNA with 0, 1, or 5 teeth were injected into mice via i.m. and i.d. routes. Tooth dose was 0.0047 μg for 0.01 μg mRNA, 0.0014 μg for 0.03 μg mRNA, 0.047 μg for 0.1 μg mRNA, and 0.014 μg for 0.3 μg mRNA, respectively. n = 4. (C and D) Luciferase expression was evaluated after i.m. injection of iLNP (C) and after i.m. and i.d. injection of PMs (D). Only expression at the muscle was quantified in (C). Representative images at 4 h are shown. n = 5 in (C) and n = 3 in (D). In i.m. injection, OVA mRNA dose for each injection was 20 μg, and tooth dose was 0.93 μg for 1 tooth and 4.7 μg for 5 teeth, respectively. In i.d. injection, OVA mRNA dose for each injection was 12 μg, and tooth dose was 0.56 μg for 1 tooth and 2.8 μg for 5 teeth, respectively.